Linked-In: Design and Efficacy of Antibody Drug Conjugates in Oncology

Jonathan Feld, Stefan K. Barta, Carolina Schinke, Ira Braunschweig, Yiyu Zhou and Amit K. Verma _

PDF  |  HTML  |  How to cite

Oncotarget. 2012; 4:397-412. https://doi.org/10.18632/oncotarget.924

Metrics: PDF 3662 views  |   HTML 3393 views  |   ?  


Jonathan Feld1,*, Stefan K. Barta1,*, Carolina Schinke1, Ira Braunschweig1, Yiyu Zhou1, Amit K. Verma1

1 Department of Medicine, Albert Einstein College of Medicine, Bronx, NY

* Denotes equal contribution


Amit K. Verma, email:

Keywords: antibody drug conjugates, oncotargets, immunotoxins

Received: March 10, 2013 Accepted: March 24, 2013 Published: March 26, 2013


The use of antibody drug conjugates (ADCs) as targeted chemotherapies has successfully entered clinical practice and holds great promise. ADCs consist of an antibody and toxin-drug combined together via a chemical linker. While the antibody and drug are of vital importance in the direct elimination of cancer cells, more advanced linker technology was instrumental in the delivery of more potent drugs with fewer side effects. Here, we discuss the preclinical experience as well as clinical trials, with a specific emphasis on the clinical outcomes and side effects, in addition to linker strategies for five different ADCs, in order to describe different approaches in the development of this new class of anticancer agents. Brentuximab vedotin is approved for use in Hodgkin’s lymphoma and Trastuzumab emtansine is approved for breast cancer. Combotox, Inotuzumab Ozogamicin, and Moxetumomab Pasudotox are in various stages of clinical development and are showing significant efficacy in lymphoid malignancies. These ADCs illustrate the promise and future potential of targeted therapy for presently incurable malignancies.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 924